Anti-ETAR and anti-AT1R autoantibodies are elevated in patients with endstage cystic fibrosis

Autoantibodies against endothelin-1 type A receptor (ETAR) are present in systemic sclerosis complicated by lung fibrosis and pulmonary hypertension. As increased serum levels and local overproduction of endothelin-1 in the airways are reported in cystic fibrosis (CF) patients, we reasoned that anti-ETAR antibodies could be prevalent in endstage CF patients prior to lung transplantation (LTx). Also, ETAR autoantibodies are frequently associated with autoantibodies against the angiotensin II type 1 receptor (AT(1)R). We analyzed the presence of anti-ETAR and anti-AT(1)R autoantibodies in 43 LTx patients (chronic obstructive pulmonary disease (COPD), n = 20; CF, n = 13; interstitial lung disease (ILD), n = 1). We observed overall higher anti-ETAR and anti-AT(1)R autoantibody titers in sera taken prior to LTx in the CF patient group as compared to COPD. No difference was found in autoantibody levels between patients with CF versus LLD. In sera taken post-LTx we found the same difference in anti-ETAR and anti-AT(1)R autoantibody titers between patients with CF versus COPD. No difference was found in antibody titers between sera taken prior to or 6 months after LTx. There was no association between autoantibody levels and other relevant demographic parameters, and we found no association between autoantibody titers and the development of the bronchiolitis obliterans syndrome. Both autoantibody titers were strongly correlated. We hypothesize that due to prolonged exposure to bacterial infection, increased levels of AT(1)R and ETAR result in a deregulated immune response causing autoantibody formation. Further research is expedient to elucidate the occurrence of autoantibodies against ETAR and AT(1)R and their role in disease progression. (C) 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.